Program Outline

The program will feature a mix of presentations, panels and workshops from invited international and Australasian speakers, as well as submitted oral presentations.

Times are based on Sydney time AEST (UTC +10)

Tuesday, 20 April, 2021

9:45 AM - 9:55 AM

Welcome

10:00 AM - 10:40 AM

Plenary 1: PRS: The basics - Prof Naomi Wray

10:45 AM - 11:25 AM

Plenary 2: Polygenic risk scores: from theory into practice - Dr Mark McCarthy

11:30 AM - 12:10 PM

Submitted Abstracts - Session 1

Predictive performance of polygenic risk scores for cardiovascular disease in older adults	Dr Moeen Riaz
Higher genetic risk for melanoma is associated with improved survival from melanoma	Dr Mathias Seviiri
Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts	Dr Julia Steinberg

12:10 PM - 12:35 PM

Lunch Break & Networking ( Tues)

12:40 PM - 12:55 PM

Posters

Exploring the genetic overlap of stuttering, neuropsychiatric disorders, and sex hormones, using polygenic risk scores	Dr Victoria Jackson
Role of APOE and polygenic risk score for dementia and cognition in older adults	Dr Moeen Riaz

1:00 PM - 1:40 PM

Plenary 3: Trans-ancestry polygenic prediction: what are we missing? - Dr Loic Yengo

1:45 PM - 2:25 PM

Plenary 4: Polygenic risk scores for prediction of breast cancer risk in Asian women - Prof. Dr. Teo Soo-Hwang

2:30 PM - 3:05 PM

Submitted Abstracts - Session 2

Integrating polygenic risk and LDL-C into an absolute risk model for Coronary Artery Disease Dr George Busby

High-resolution portability of 245 polygenic scores when derived and applied in the same cohort Dr Florian Privé

Close Day 1

Wednesday, 21 April, 2021

10:00 AM - 10:30 AM

Plenary 5: Polygenic scores: Potential for clinical utility and target identification - A/Prof Mike Inouye

10:35 AM - 11:00 AM

Presentation: Cross ancestry genetics in glaucoma - Prof Stuart MacGregor

11:05 AM - 12:10 PM

Submitted Abstracts - Session 3

Datamining, DNA sequencing and polygenic risk scores in Familial Hypercholesterolaemia Dr Patrick Gladding

Polygenic Score Modifies Risk for Alzheimer’s Disease in APOE e4 Homozygotes at Phenotypic Extremes Dr Aamira Huq
Brian Fulton-Howard

Polygenic risk scores improves prediction of keratinocyte cancer following immunosuppression A/Professor Matthew Law

Prediction of HF in UK Biobank using genetic information and traditional risk factors Mr Xiaodong Mo

Integrating causal inference and transcriptomic data with polygenic risk scoring to prioritise drug repurposing candidates Mr. William Reay

12:10 PM - 12:55 PM

Lunch Break & Networking (Wed)

12:15 PM - 12:55 PM

Posters (Wed)

Distinct profile of metabolite polygenic risk scores may distinguish perinatal depression from major depressive disorder Ms Jackie Kiewa

Using cloud-based machine-learning GWAS platform VariantSpark to build cardiovascular disease risk models Letitia Sng

1:00 PM - 2:15 PM

Communication Session

GP attitudes to providing polygenic risk information for risk-stratified population cancer screening: qualitative interviews	Ms Kate Dunlop
Informed choice and attitudes regarding a genomic test for colorectal cancer in general practice	Sibel Saya
Knowledge, attitudes and expectations for polygenic risk testing to evaluate cancer risk in clinical practice	Miss Courtney Wallingford

Includes 3 submitted oral presentations & a Panel Discussion on Communicating Polygenic Scores

2:20 PM - 3:05 PM

Plenary 6: Determining if polygenic score analysis can provide clinical utility - Dr Sowmiya Moorthie

Thursday, 22 April, 2021

10:00 AM - 10:25 AM

Plenary 7: PRIMO: PRS as a modifier of mendelian effect - A/Prof Paul James

10:30 AM - 10:55 AM

Plenary 9: Implementing polygenic risk scores for cancer in primary care - Prof Jon Emery

11:00 AM - 11:40 AM

Submitted Abstracts - Session 4

Attitudes toward glaucoma genetic risk assessment among affected individuals Dr Georgina Hollitt

Motivations and barriers to participation in a study on melanoma genomic risk: a mixed-methods analysis Ms Gabriela Mercado

11:45 AM - 12:25 PM

Plenary 8: Integrating polygenic risk scores into risk prediction models to improve population-level risk stratification - Ms Sarah Kalia

12:25 PM - 1:15 PM

Lunch Break & Networking (Thurs)

1:20 PM - 1:45 PM

Plenary 10: Clinical PRS Validation Studies in a Large Prospective Australian Cohort: ASPREE - Dr Paul Lacaze

1:50 PM - 2:15 PM

Plenary 11: Managing Your Risk Study findings & implementation considerations - Prof Anne Cust

2:20 PM - 3:00 PM

Panel Session: PRS implementation in different contexts: commercial, academic, clinical

3:00 PM - 3:05 PM

Closing